**VPA10454/034/001**

**Eprinex Multi 5 mg/ml pour-on solution for cattle, sheep and goats**

| Variation | Summary | Date |
|---|---|---|
| Vet - B3 a) | VNRA - Vet - B3 a) - a) Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier) - B3 a) Changes to the quality part of the dossier: Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier) | 16/01/24 |
| Vet - C1 | VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) | 14/08/23 |
| Vet - C6 | VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 | 14/08/23 |
| Vet - C6 | VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 | 01/06/23 |
| Vet - C1 | VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) | 21/04/23 |
| Vet - A1 a) | VNRA - Vet - A1 a) - a) Change in the name or address or contact details of the marketing authorisation holder - A1 a) Administratvie changes: Change in the name or address or contact details of the marketing authorisation holder | 29/03/23 |
| Vet - B3 e) | VNRA - Vet - B3 e) - e) Deletion of a test procedure - B3 e) Changes to the quality part of the dossier: Deletion of a test procedure — for the active substance or a starting material, reagent or intermediate of the active substance; —for the immediate packaging of the active substance; — for an excipient or the | 19/01/23 |

| | | |
|---|---|---|
| | finished product; —for the immediate packaging of the finished product | |
| Vet - B12 b) | VNRA - Vet - B12 b) - b) Minor changes to an approved test procedure (starting material, excipient) - B12 b) Changes to the quality part of the dossier: Minor changes — to an approved test procedure — for a starting material, reagent or intermediate used in the manufacturing process of the active substance; — for an excipient | 19/01/23 |
| Vet - B10 b) | VNRA - Vet - B10 b) - b) Addition of a new in-process test and limits - B10 b) Changes to the quality part of the dossier: Change to in-process tests or limits applied during the manufacture of the active substance —addition of a new in-process test and limits | 20/12/22 |
| Vet - A1 a) | VNRA - Vet - A1 a) - a) Change in the name or address or contact details of the marketing authorisation holder - A1 a) Administratvie changes: Change in the name or address or contact details of the marketing authorisation holder | 15/12/22 |
| C.I.6.a | II - C.I.6.a - a) Addition of a new therapeutic indication or modification of an approved one - C.I.6.a - SAFETY, EFFICACY, PHARMACOVIGILANCE CHANGES - HUMAN AND VETERINARY MEDICINAL PRODUCTS - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 13/12/22 |
| C.I.6.a | II - C.I.6.a - a) Addition of a new therapeutic indication or modification of an approved one - C.I.6.a - SAFETY, EFFICACY, PHARMACOVIGILANCE CHANGES - HUMAN AND VETERINARY MEDICINAL PRODUCTS - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 13/12/22 |
| C.I.13 | II - C.I.13 - C.I.13 Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority* - C.I.13 - SAFETY, EFFICACY, PHARMACOVIGILANCE CHANGES - HUMAN AND VETERINARY MEDICINAL PRODUCTS - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority* | 13/12/22 |
| Vet - A1 a) | VNRA - Vet - A1 a) - a) Change in the name or address or contact details of the marketing authorisation holder - A1 a) Administratvie changes: Change in the name or address or contact details of the marketing authorisation holder | 27/09/22 |
| A.4 | IA - A.4 - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - A.4 - ADMINISTRATIVE CHANGES - Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or | 15/03/22 |

| | | |
|---|---|---|
| | intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) | |